Business Wire

PA-PCI-PHARMA-SERVICES

28.9.2020 12:02:47 CEST | Business Wire | Press release

Share
PCI Pharma Services Introduces First-of-its-Kind Digital Platform to Provide Clients with Real-Time Supply Chain Data and Analytics

PCI Pharma Services (PCI) , a leading pharmaceutical and biopharmaceutical global outsourcing solutions provider today announced the launch of pci | bridge , an innovative digital platform that will give customers immediate visibility into their clinical and commercial supply chain, and provide instantaneous data and insights to inform decision-making. Created using an agile development process whereby key clients collaborated and provided input, PCI built an industry-leading digital interface that delivers greater transparency to clients – saving time and resources to ultimately help bring life-changing therapies to patients faster. The launch of pci | bridge is one of many initiatives that PCI has undertaken to incorporate digital transformation as core to its business strategy.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200928005059/en/

“At PCI, we are always looking to the future and could see the potential that technology and digital systems held for the pharmaceutical supply chain industry,” said Salim Haffar, Chief Executive Officer, PCI Pharma Services. “Twelve months ago, we made the deliberate decision as an organization to invest more in this area, with the goal of enhancing client experiences, digitizing business processes and aligning our IT to scale as we grow. The launch of pci | bridge represents a key milestone achievement in our digital transformation journey. We believe our unique offering will simplify how our clients interact with us and create a leading-edge client experience.”

A direct connection between PCI and clients, the platform will make real-time information readily accessible to clients including inventory, production, distribution and shipping data, presented in organized, customizable formats. The platform also features a document repository where electronic paperwork can be stored and accessed in one place, and signatures secured on the platform.

“Having a fully functioning supply chain, whose foundation is built on digitally-enabled capabilities and technologies, means we can be more adept at moving resources, assets and inventory – quickly and effectively,” said Wayne Hull, Chief Digital and Technology Officer, PCI Pharma Services. “We are embracing new technologies at PCI because they improve client experiences, give greater visibility into the supply chain, and provide data insights to optimize efficiencies and mitigate risks.”

The technology behind pci | bridge will closely and very securely integrate PCI’s systems with those of clients so that the supply chain can be easily managed by both parties. One significant advantage is removing manual processes that are often time intensive for both sides.

“Seeking input from multiple customers to understand how we hope to use the platform and previewing iterations with us is invaluable in terms of structuring the tool so it can actually be helpful to our work,” said Wendy Xia, Senior Director, Head of Supply Chain at Agios Pharmaceuticals, a key PCI client who collaborated with the company on pci | bridge . “I am very excited about my team using pci | bridge because I think it will greatly increase productivity and efficiency on both ends.”

“The benefits I see of using pci | bridge is that is that it eliminates the need for clients to constantly reach out to the project teams for updates. Now, we will have that information at our fingertips and can instead focus on the bigger picture with PCI, such as what’s coming next,” added Kevin Gregorczyk, Director, Development Operations at eFFECTOR Therapeutics, another key PCI client who participated in the development process.

Post-launch, PCI will continue to evolve and update pci | bridge features to meet client needs.

To learn more about pci | bridge , click here .

About PCI Pharma Services

The global healthcare industry trusts PCI for the drug development solutions that increase their products’ speed to market and opportunities for commercial success. Only PCI brings the proven experience that comes with more than 50 successful product launches a year and over five decades in the healthcare business. Leading technology and continued investment enable us to address global development needs throughout the product life cycle — from Phase I Clinical trials through commercialization and ongoing supply. Our clients view us as an extension of their business and a collaborative partner, with the shared goal of improving patients’ lives. For more information, please visit www.pci.com or follow us on Twitter at @PCI_Social .

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

BRUNO to Showcase Acclaimed Lifestyle and Travel Collections at Ambiente 20262.2.2026 09:00:00 CET | Press release

Tokyo-based lifestyle company BRUNO, Inc. (Headquarters: Shinjuku-ku, Tokyo; President & CEO: Tetsu Shiota), dedicated to the planning, development, and sale of lifestyle products, is pleased to announce its participation in Ambiente—the world’s leading international consumer goods trade fair held in Frankfurt, Germany. The company will showcase its two flagship brands: "BRUNO," a lifestyle brand dedicated to "enjoying life to the fullest," and "MILESTO," a premium travel brand designed for those who "live every day like a journey." This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260202663769/en/ Our participation in Ambiente marks a pivotal step in our global expansion strategy, as outlined in our current medium-term management plan. We are excited to introduce BRUNO and MILESTO—brands that have earned immense loyalty in Japan—to a global audience. Our exhibit showcases a curated selection of flagship products and latest inn

Reges Elektrik Acquires the Demirli Wind Power Plant, One of Türkiye’s Most Significant Wind Energy Projects2.2.2026 09:00:00 CET | Press release

Reges Elektrik, a dynamic and innovative leader in the Turkish energy sector, has announced the acquisition of Tuşpa Enerji Üretim A.Ş. as part of its strategic growth roadmap. Through this landmark acquisition, Reges Elektrik will launch electricity production at the 70 MW Demirli Wind Power Project, located in the Kaman district of Kırşehir. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260126059611/en/ From left to right: Enver Altuncu, General Manager and Board Member at Reges Elektrik; Cansu Ünal Öngören, CFO and Board Member at Reges Elektrik; Geert Dooms, General Manager at RES Türkiye; Kağan Gilik, Deputy General Manager at RES Türkiye. Acquired from RES Türkiye, a subsidiary of RES Group—the world’s largest independent renewable energy company—the Demirli Project represents a pivotal milestone in Reges Elektrik’s decisive expansion into energy production. With this investment, the company scales its operations to i

Teledyne FLIR Defense Wins $17.5 Million Contract from armasuisse to Deliver Black Hornet 4 Nano-Drones for Dismounted and Vehicle-Integrated Reconnaissance2.2.2026 08:00:00 CET | Press release

Delivery of the Black Hornet UAV systems to Swiss Armed Forces will include drones with software and integration kit specially designed to work with Piranha 8x8 vehicle digital infrastructureWork shows promise and market potential for UAS armored vehicle integrations to enhance tactical operations Teledyne FLIR Defense, part of Teledyne Technologies Incorporated (NYSE:TDY), announced that it has received a $17.5 million contract from armasuisse, the Swiss Federal Office of Defence Procurement, to deliver a large number of Black Hornet® 4 Personal Reconnaissance Systems, one of the world’s most advanced and widely deployed nano-drones. Black Hornet 4 was selected as an airborne dismountable Intelligence, Surveillance, and Reconnaissance (ISR) capability sensor for armasuisse’s Piranha 8x8 Armored engineering vehicle program. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260201061637/en/ Teledyne FLIR Defense has won a $17.5

Danish C-UAS Startup Shotling Raises €700K Oversubscribed Pre-Seed (Myriad-IPO CLUB-EIFO) for Anti-Drone Shotgun2.2.2026 07:35:00 CET | Press release

Shotling, a Danish defense technology startup specializing in kinetic short-range counter-UAS (C-UAS) systems, today announced the closing of a pre-seed financing round with €700K committed out of a targeted €500K. The round is led by Myriad Defense Fund, with co-investment from IPO CLUB’s Fund II America 2030, and a non-dilutive match-loan granted by EIFO, the Export and Investment Fund of Denmark, supporting Shotling’s mission to deliver rapid-fire modular shotgun systems against FPV drones and loitering munitions—as the global counter-UAS market accelerates towards $10B by 2030, with kinetic defense segment showing strong momentum (25%+ CAGR). Shotling’s rotary shotgun system provides unmatched close-range defense (50–100m) against the rapidly growing threat of kamikaze drones, combining a gatling-style design, with novel, high-capacity magazines, and firing rates up to 3,000 RPM using standard or tungsten-based 12-gauge shells. With deep expertise in weapons engineering and active

Galderma Announces U.S. FDA Acceptance of RelabotulinumtoxinA Biologics License Application Resubmission2.2.2026 07:00:00 CET | Press release

The United States (U.S.) Food and Drug Administration (FDA) has accepted the Biologics License Application (BLA) resubmission for RelabotulinumtoxinA for the temporary improvement of moderate-to-severe glabellar lines (frown lines) and lateral canthal lines (crow’s feet) in adults RelabotulinumtoxinA is designed to optimize molecule integrity to deliver fast onset of action as early as Day 1 and sustained results for six months for frown lines and crow’s feet and has been approved in over 20 markets, including in the European Union1-3 Galderma (SIX: GALD) today announced that the U.S. FDA has accepted the BLA resubmission for RelabotulinumtoxinA for the temporary improvement of moderate-to-severe glabellar lines (frown lines) and lateral canthal lines (crow’s feet) in adults. Galderma has worked closely with the U.S. FDA to implement adjustments to its manufacturing process. Galderma is committed to using its expertise and heritage in the neuromodulator space to develop next-generation

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye